Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

3.9K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.9K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

544
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
544
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

7.6K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
7.6K
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

1.9K
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
1.9K
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

2.5K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.5K
Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

6.7K
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
6.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Precision Temperature Control of Volume Phase Transition in Biocompatible PEG-Based Nanogels for Triggered Drug Release.

ACS nano medicine·2026
Same author

Decreased Thigh Muscle Cross-Sectional Area Following Anterior Cruciate Ligament Injury Depends on Concomitant Meniscal Injury and Subject Sex.

Journal of orthopaedic research : official publication of the Orthopaedic Research Society·2026
Same author

PGC1α expression using targeted redox-responsive nanogels protects against prostate cancer in vivo.

Journal of controlled release : official journal of the Controlled Release Society·2026
Same author

Correction: Cell docking inside microwells within reversibly sealed microfluidic channels for fabricating multiphenotype cell arrays.

Lab on a chip·2026
Same author

Multiplexed Nanoparticle Protein Corona Enables Accurate and Precise Deep Plasma Proteomics.

Journal of proteome research·2025
Same author

Effect of Size and Targeting Agent on Biodistribution of Polystyrene Nanoparticles in Apolipoprotein E Knock-Out and Wild-Type Mice.

Diagnostics (Basel, Switzerland)·2025

Related Experiment Video

Updated: Mar 24, 2026

Synthesis of Functionalized 10-nm Polymer-coated Gold Particles for Endothelium Targeting and Drug Delivery
10:38

Synthesis of Functionalized 10-nm Polymer-coated Gold Particles for Endothelium Targeting and Drug Delivery

Published on: January 15, 2018

13.2K

Nanomedicines for Endothelial Disorders.

Bomy Lee Chung1, Michael J Toth2, Nazila Kamaly3

  • 1David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology; Department of Chemical Engineering, Massachusetts Institute of Technology.

Nano Today
|March 9, 2016
PubMed
Summary

Nanomedicine offers new therapeutic strategies for diseases linked to endothelial dysfunction, a common factor in diabetes, cardiovascular diseases, and cancer. This review explores current treatments and nanomedicine

Keywords:
atherosclerosiscancerdiabetesendothelial disorderendotheliumnanomedicinepermeability

More Related Videos

Assessing Endothelial Vasodilator Function with the Endo-PAT 2000
07:46

Assessing Endothelial Vasodilator Function with the Endo-PAT 2000

Published on: October 15, 2010

44.6K
Ultrasound Assessment of Endothelial Function: A Technical Guideline of the Flow-mediated Dilation Test
06:35

Ultrasound Assessment of Endothelial Function: A Technical Guideline of the Flow-mediated Dilation Test

Published on: April 27, 2016

19.0K

Related Experiment Videos

Last Updated: Mar 24, 2026

Synthesis of Functionalized 10-nm Polymer-coated Gold Particles for Endothelium Targeting and Drug Delivery
10:38

Synthesis of Functionalized 10-nm Polymer-coated Gold Particles for Endothelium Targeting and Drug Delivery

Published on: January 15, 2018

13.2K
Assessing Endothelial Vasodilator Function with the Endo-PAT 2000
07:46

Assessing Endothelial Vasodilator Function with the Endo-PAT 2000

Published on: October 15, 2010

44.6K
Ultrasound Assessment of Endothelial Function: A Technical Guideline of the Flow-mediated Dilation Test
06:35

Ultrasound Assessment of Endothelial Function: A Technical Guideline of the Flow-mediated Dilation Test

Published on: April 27, 2016

19.0K

Area of Science:

  • Vascular Biology and Nanomedicine

Background:

  • The endothelium, lining blood and lymphatic vessels, is crucial for homeostasis.
  • Endothelial dysfunction contributes to the pathology of diabetes, cardiovascular diseases, and cancer.
  • Targeting the endothelium presents a therapeutic opportunity across various diseases.

Purpose of the Study:

  • To review current therapies for diseases involving endothelial dysfunction.
  • To highlight the potential of nanomedicine in treating these conditions.

Main Methods:

  • Literature review of existing therapies.
  • Exploration of nanomedicine applications for endothelial dysfunction.

Main Results:

  • Nanomedicine offers novel approaches for diseases linked to endothelial dysfunction.
  • Targeted therapies can address common pathological pathways.

Conclusions:

  • Nanomedicine holds significant promise for treating diseases associated with endothelial dysfunction.
  • Further research into nanomedicine can expand therapeutic options.